Our Product Pipeline


Talaris Therapeutics is deploying its revolutionary cell therapy technology across multiple therapeutic areas of high unmet need.

In addition to our ongoing Phase 3 trial in living donor kidney transplant patients, we have received FDA IND acceptance to initiate a Phase 1/2a trial of FCR001 in rapidly progressive diffuse scleroderma. Planned future clinical studies will explore the potential of FCR001 to enable patients who have previously received a living donor kidney transplant to be weaned off their chronic immunosuppression medications, as well as its potential to benefit patients who receive an organ transplant from a deceased donor.